NRx Pharmaceuticals Reports Q2 Earnings, Updates on Ketamir-2 Trial

NRx Pharmaceuticals reported a Q2 loss per share of (98c), compared to (75c) YoY. The company has $2.9M in cash and believes it will support operations into 2026 and reach expected regulatory inflection points. CEO Jonathan Javitts highlighted progress with the company's lead programs and the attraction of a group of fundamental biotechnology investors. MIRA Pharmaceuticals completed the Single Ascending Dose portion of its Phase 1 clinical trial for oral Ketamir-2, demonstrating a favorable safety and tolerability profile.